"There could be a competition to get the first Kevetrin results into a peer reviewed journal or a major industry presentation, or not."

There won't be. CTIX sewed that up tightly in their agreements with the hospital sponsored studies, I'm sure. The local Kevetrin study is the intellectual property of CTIX, not DF. CTIX gets to call the shots. The hospitals that are sponsoring study of the agent themselves must have signed serious disclosure and confidentiality agreements written around the intellectual and now physical property of the drug molecule. The only thing theses sponsoring institutions are likely to own are the research rights and research publication rights. But CTIX will have tied them up around publication and results release. Those will happen on the company's schedule, even if they didn't sponsor the study...

This is where real cloak and dagger stuff often enters the research industry. It can read like a dangerously awesome spy novel sometimes - as researchers are seeded in to steal the scoop...